Four male patients were admitted to the respiratory department for hemoptysis (Table 1), and the most frequent cause was lung cancer. TA was administered through a jet nebulizer with a flow rate of 5 L of oxygen per minute, and doses of 2.5 or 5 mL were prescribed according to clinical decision, using a concentration of 500 mg/5 mL. The average duration of nebulization was 15 min. In all patients, the bleeding was classified as moderate with a mean hemoptysis volume of 100 mL per day, without severe hypotension, tachycardia, or hypovolemic shock. Inhaled TA was used with acceptable control of bleeding and no incidence of systemic effects. As to local effects, one patient presented a bronchospasm after the third dose of TA, which was successfully treated with short-term bronchodilators.